Autologous stem cell transplantation for T-cell lymphomas.
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of T-cell malignancies characterized by a very poor outcome. The optimal treatment for PTCLs remains controversial. The role of stem cell transplantation in PTCLs has been investigated; however, no randomized control studies specifically dedicated to PTCLs are currently available. Several retrospective and prospective studies have suggested that high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) may improve the survival in patients with chemosensitive T-cell lymphoma, either upfront or as salvage treatment. This review provides a summary of the current literature with the intent to explore the role of ASCT in various clinical scenarios.
Giulia
G
Perrone
Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Perrone
P
Giulia
Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Department of Hematology, University of Milan, Milano, Italy. Electronic address: paolo.corradini@unimi.it.
Paolo
P
Corradini
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D016399:Lymphoma, T-Cell / Q000628:therapy*; D012008:Recurrence; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous